CAPLIPOINT2024-04-012024-06-30 CAPLIPOINT2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member CAPLIPOINT2024-06-30 CAPLIPOINT2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524742 CAPLIPOINT NOTLISTED Caplin Point Laboratories Limited Equity 2024-04-01 2025-03-31 2024-08-07 2024-07-31 INR Crores First quarter 11:15:00 12:45:00 2024-08-07 2024-08-07 Not applicable Single segment Pharmaceuticals 2024-04-01 2024-06-30 Unaudited Consolidated 4589600000.00 185600000.00 4775200000.00 636500000.00 744800000.00 473500000.00 401500000.00 500000.00 159600000.00 815200000.00 3231600000.00 1543600000.00 0.00 1543600000.00 293800000.00 800000.00 294600000.00 0.00 1249000000.00 0.00 0.00 0.00 200000.00 1249200000.00 46800000.00 1296000000.00 1239700000.00 9500000.00 1286500000.00 9500000.00 152000000.00 2 16.32 16.24 0.00 0.00 16.32 16.24 0.00 0.00 0.00 1) The above Consolidated Financial Results for the quarter ended June 30, 2024 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on August 7, 2024. 2) The unaudited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ( the Act ) read with relevant rules issued thereunder ( Ind AS ) and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI ( Listing Obligations and Disclosure Requirments) Regulations, 2015. 3) The Company is engaged in the sole activity of carrying on the business of Pharmaceutical Formulations and therefore, has only one reportable segment in accordance with Ind AS 108 Operating Segments . Hence no separate segment reporting is applicable to the Company. 4) During the quarter ended June 30, 2024 the Company has alloted 68,550 equity shares of Rs. 2/- each under the Employees Stock Option Schemes and the total number of equity shares of the Company stands at 7,60,10,296 as at June 30, 2024. The Company had allotted NIL shares and 31,000 shares during the quarter ended March 31, 2024 and June 30, 2023 respectively. Other Expenses 815200000.00 0.00 Exchange difference in translating the financial statements of foreign operations 46800000.00 46800000.00 0.00